LOS ANGELES--(BUSINESS WIRE)--Neural Analytics, a medical device company developing and commercializing technology to measure, diagnose and track brain health, announced today that CEO Leo Petrossian, PhD will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 2:00 p.m. ET at the Westin Grand Central in New York, NY. Dr. Petrossian will provide a corporate overview and discuss the Company’s leading brain health diagnostic, monitoring, and medical device systems.
Neural Analytics recently received both FDA clearance and CE Mark for its next generation ultrasound device, the Lucid M1 Transcranial Doppler Ultrasound System™ (Lucid System). The Lucid System is an all-in-one ultrasound system designed for measuring and displaying cerebral blood flow velocities and monitoring of patients with brain disorders. The Lucid System is currently available in the U.S and Europe.
The company is also conducting a feasibility study with the Erlanger Health System in Chattanooga, Tennessee to evaluate the Lucid System for patients suffering an acute ischemic stroke.
About Neural Analytics Inc.
Neural Analytics was founded in 2013 to create products and services to measure, diagnose and track brain health. They combine leading data science with cutting edge hardware to allow first responders and clinicians to accurately assess and monitor brain health issues. Their devices are designed to be portable, autonomous, reliable, and produce precise and objective physiological measurements for medical responder monitoring of neural disorders.
More information is available at http://www.neuralanalytics.com.